BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis



Status:Archived
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:October 2008
End Date:September 2010

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB023 (Anti-TWEAK) Administered to Subjects With Rheumatoid Arthritis.


Phase I study designed to determine the safety and tolerability of a single dose of BIIB023
administered intravenously versus placebo to subjects with RA.



We found this trial at
4
sites
Clinical Trial Facility in Birmingham Alabama
Birmingham, Alabama
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Research Centre
Duncansville, Pennsylvania
?
mi
from
Duncansville, PA
Click here to add this to my saved trials
Clinical Trial Facility in Oklahoma City Oklahoma
Oklahoma City, Oklahoma
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Research Centre
Palm Desert, California
?
mi
from
Palm Desert, CA
Click here to add this to my saved trials